A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer First Report from the Scandinavian Prostatic Cancer Group Study No. 6

Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer

“…However, 62% of their prostate cancer patients died primarily from their malignancy, while only one third neither suffered nor died from their disease. In Scandinavia the majority (80%) of newly diagnosed patients in the period 1995 Á1998 still did not receive primary therapy with curative intent [26]. However, a Swedish pivotal randomised study indicates a clear reduction in cancer specific mortality after radical prostatectomy compared with watchful waiting, whereas there was no difference in overall survival [27].…”

Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer

“…48 A further trial specifically evaluated the impact of bicalutamide on sexual interest and function (measured using a shortened version of the Golombok Rust Inventory of Sexual Early hormonal therapy in men with prostate cancer AV Kaisary Satisfaction), and, after 1 y, found little differences from placebo on these parameters. 54 Mild-to-moderate gynaecomastia and breast pain are the most frequent side effects of non-steroidal antiandrogen therapy. 55 The reported incidence of gynaecomastia is similar for the three available agents: 37-68% with bicalutamide; 21-80% with flutamide; and 50% with nilutamide.…”

Off-Label-Verordnungen in der Onkologie

“…Eine Gesamtauswertung aller 3 Studien nach 3 Jahren zeigte beim lokalisierten und beim lokal fortgeschrittenen PCa eine signifikante Minderung der Progressionshäufigkeit in der Bicalutamid-Gruppe (9%) im Vergleich zur Kontrollgruppe (13,8%) [7]. Dieser positive Effekt war bei lokal fortgeschrittenen Tumoren fast doppelt so groß wie bei lokal begrenzten Tumoren [7,8]. Eine Aussage über einen potenziellen Überlebensvorteil durch Bicalutamid ist derzeit noch nicht möglich.…”